tiprankstipranks
Lexicon announces completion of enrollment in Phase 2B PROGRESS study
PremiumThe FlyLexicon announces completion of enrollment in Phase 2B PROGRESS study
2M ago
Lexicon price target lowered to $4 from $6 at H.C. Wainwright
Premium
The Fly
Lexicon price target lowered to $4 from $6 at H.C. Wainwright
2M ago
Lexicon to eliminate commercial organization, focus on clinical development
Premium
The Fly
Lexicon to eliminate commercial organization, focus on clinical development
2M ago
Lexicon Pharmaceuticals options imply 14.8% move in share price post-earnings
PremiumThe FlyLexicon Pharmaceuticals options imply 14.8% move in share price post-earnings
3M ago
Lexicon announces JASN publishes sotagliflozin data
Premium
The Fly
Lexicon announces JASN publishes sotagliflozin data
3M ago
Lexicon to present data from two studies related to LX9851
Premium
The Fly
Lexicon to present data from two studies related to LX9851
3M ago
Lexicon announces new analysis of Phase 3 SCORED trial
PremiumThe FlyLexicon announces new analysis of Phase 3 SCORED trial
3M ago
Lexicon’s LX9211 progressing ahead of schedule, says H.C. Wainwright
Premium
The Fly
Lexicon’s LX9211 progressing ahead of schedule, says H.C. Wainwright
3M ago
Lexicon completes screening in Phase 2B progress study of LX9211
Premium
The Fly
Lexicon completes screening in Phase 2B progress study of LX9211
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100